We have previously reported obtaining two monoclonal antibodies (mAb) against the human gp130 interleukin-6 (IL-6) transducer which made possible the dimerization of gp130 and the activation of several IL-6-driven functions when used together. We report here that these mAb induce gp130-mediated signaling in human myeloma cells and support the survival and the long-term growth of five IL-6-dependent human myeloma cell lines. Their agonist activity is not affected by neutralizing antibodies to IL-6 or IL-6R. These mAb induce a transient proliferation of primary myeloma cells from most patients with multiple myeloma. Again, IL-6 inhibitors do not affect this agonist activity. By using highly purified primary myeloma cells, we found that these anti-gp130 mAb supported the long-term survival of primary myeloma cells from five patients with primary plasma cell leukemia but failed to induce their long-term growth. For patients with fulminant disease and secondary extramedullary proliferation, the antibodies supported a long-term survival and growth, and anti-gp130 mAbdependent cell lines were obtained. For patients with medullary involvement only, a co-stimulatory signal is necessary, together with gp130 activation, to trigger cell survival and cycling. Leukemia (2000) 14, 188-197. 
Introduction
Multiple myeloma (MM) is a neoplasm affecting the late B cell differentiation stage, the plasma cell. This disease is universally fatal with a mean survival of 3 years. 1 Thus, there is a need to understand the mechanisms underlying tumor progression and to identify strategies able to control the disease. Interleukin-6 (IL-6) has been widely recognized as a major survival and growth factor for malignant plasma cells in murine plasmacytomas [2] [3] [4] as well as in human MM. 5 This cytokine blocks the dexamethasone-induced apoptosis of fresh myeloma cells, 6, 7 transiently stimulates their proliferation in vitro 8, 9 and makes it possible to obtain IL-6-dependent human myeloma cell lines (HMCL) from patients with terminal disease. [10] [11] [12] IL-6 is part of a cytokine family comprising interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF). 13 These cytokines all activate the common signal transducing subunit gp130. These various IL-6-type cytokines can support the survival and growth of myeloma cell lines nearly as efficiently as IL-6 does but their precise role in vivo has not been elucidated. [14] [15] [16] [17] According to a general mechanism reported for cytokines and cytokine receptors, 18 these gp130 cytokines induce the homodimerization of gp130 (IL-6, IL-11) or heterodimerization of gp130 with another transducer chain (LIF, OSM, CNTF). 13, 19 In the case of IL-6, the final complex is hexameric and associ- ates two molecules of IL-6, of IL-6R and of gp130. 20 A soluble form of IL-6R (sIL-6R) is found in body fluids. sIL-6R is an agonist molecule for IL-6 and shares with membrane-bound IL-6R the ability to activate the gp130-signaling cascade. Two recent reports have described the obtaining of myeloma cell lines whose growth was supported by bone marrow stromal cells. 21, 22 The stromal cell supernatants could be replaced by a combination of IL-6 and sIL-6R but not by IL-6 alone. These data suggest that membrane IL-6R expression on myeloma cells might be a limiting factor for IL-6-mediated gp130 signaling. We recently obtained monoclonal antibodies (mAb) to gp130. Most of these mAb inhibited the gp130-mediated signaling induced by one or various gp130 cytokines. 23 However, we have identified a pair of mAb able to induce gp130 dimerization and gp130-mediated signaling. 24 We report here that these mAb can induce gp130-mediated signal transduction in myeloma cells, support the long-term survival and growth of all our IL-6-dependent myeloma cell lines, support the survival of primary myeloma cells and make it possible to obtain anti-gp130 mAb-dependent myeloma cell lines from patients with secondary extramedullary proliferation.
Patients, materials and methods

Patients
Tumoral samples were obtained from 17 patients with MM (median age: 57 years) after approval by a local Human Investigations Committee and patients' informed consent. Three patients had stage II and 14 patients had stage III disease. Five patients had primary plasma cell leukemia (PCL). During the disease evolution, three patients presented with secondary extramedullary disease: one patient developed ascitis and two patients secondary PCL. Tumoral samples were from bone marrow for nine patients, ascitis fluid for one patient and peripheral blood for seven patients with PCL. Ten patients had IgG k MM, two IgG MM, four IgA k MM, one Bence-Jones MM.
Reagents
Recombinant IL-6 was provided by Dr Ythier (Geneva, Switzerland). The B-E8 and B-R6 neutralizing murine mAb to respectively IL-6 and IL-6R were provided by JW (Diaclone), and the MI15 anti-syndecan-1 and M91 anti-IL-6R mAb by Jean Brochier (INSERM U475). The B-R3, B-S12, B-P8 and B-T2 murine mAb to gp130 transducer were cooperatively obtained by Diaclone and our laboratory. 23 B-R3 is a neutralizing mAb unlike B-T2. 23 The M91 and B-T2 mAb were conjugated with fluorescein isothiocyanate (FITC) in our laboratory. Control murine IgG, FITC-conjugated murine IgG and FITC-conjugated F(ab)Ј 2 fragments of goat anti-mouse immunoglobulin were from Immunotech (Marseille, France). The biotinylated anti-human immunoglobulin light chain antibodies were from Caltag (San Francisco, CA, USA). Streptavidin conjugated with PerCP was from Becton Dickinson (San Jose, CA, USA). Magnetic beads coated with affinity purified sheep anti-mouse IgG were purchased from Dynal (Oslo, Norway). Rabbit phospho-specific anti-STAT 1, STAT3 and MAPK antibodies were purchased from New England Biolabs (Beverly, MA, USA), mouse anti-STAT1 and STAT3 from Transduction Laboratories (Lexington, KY, USA), and rabbit anti-ERK2 from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Cell lines
The XG-1, XG-2, XG-6, XG-10 and XG-13 cells used in this study express cytoplasmic Ig and plasma-cell antigens (Ag) (CD38 and/or syndecan-1), and lack the usual B cell Ag (CD19 and CD20). They are not infected with Epstein-Barr virus. Detailed characteristics of XG-1, XG-2, XG-6 have been reported elsewhere.
11 XG cells were grown in RPMI 1640 culture medium with 10% of fetal calf serum (FCS) and 3 ng/ml IL-6. All cell lines were free of mycoplasma, as assayed by an ELISA kit (Boehringer, Mannheim, Germany).
Proliferation and growth assay for myeloma cell lines
To investigate the effects of cytokines and anti-gp130 mAb on the proliferation of human myeloma cell lines, XG cells were washed once with culture medium, incubated for 5 h at 37°C in culture medium with 10% FCS and washed again twice in order to remove recombinant IL-6 bound to the IL-6R. Cells (10 4 cells/well in 200 l of culture medium) were then cultured in 96-well flat-bottomed microplates for 5 days in the absence or presence of IL-6 or anti-gp130 mAb. In some culture groups, 10 g/ml of a neutralizing mAb to IL-6 (B-E8) or to IL-6R (B-R6) was added at the beginning of the culture. Tritiated thymidine (0.5 Ci, 25 Ci/mM; ICN France, Orsay, France) was added for the last 8 h of culture, and tritiatedthymidine incorporation was determined as reported previously. 25 To investigate the effects of IL-6 or anti-gp130 mAb on the long-term growth of XG cells, cells were washed once with culture medium, incubated for 5 h at 37°C in culture medium with 10% FCS and washed again twice. They were then cultured at a cell concentration of 2 × 10 5 cells per ml without exogenous cytokine and 10 g/ml of a control murine mAb, or 10 g/ml of the B-E8 anti-IL-6 murine mAb, or 3 ng/ml of IL-6 plus 10 g/ml of control murine mAb; or 1 g/ml of B-S12 and B-P8 anti-gp130 mAb (0.5 g/ml each); or 1 g/ml of B-S12 and B-P8 anti-gp130 mAb (0.5 g/ml each) and 10 g/ml of the B-E8 anti-IL-6 mAb. For each culture group, XG cells were diluted every 4 days at a cell concentration of 2 × 10 5 cells/ml in fresh culture medium containing the initial cytokine and/or antibody concentrations. Results are the means of the cumulative numbers of cells generated in sextuplate culture wells.
Detection of apoptotic cells
Apoptotic cells were detected using Annexin-V-fluos (Boehringer Mannheim), which has a high affinity for phosLeukemia phatidylserine present in the outer membrane of apoptotic cells. 26 Cells were washed twice in PBS and resuspended in Annexin-V FITC solution (1:50 dilution in HEPES buffer:10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ). Cells were incubated for 15 min at room temperature before analysis on a FACScan flow cytometer (Becton Dickinson).
Purification of freshly explanted primary myeloma cells
Mononuclear cells from tumoral samples were separated on Ficoll-Hypaque. Myeloma cells were purified by using the anti-myeloma cell MI15 mAb. We have shown that the MI15 mAb recognizes syndecan-1 and that syndecan-1 is only present in tumoral samples on viable myeloma cells. 27, 28 In addition, this antigen is cleaved by chymopapain without affecting cell viability using a procedure previously described for CD34 purification which allows a large scale purification of myeloma cells. 29 To purify myeloma cells, mononuclear cells from tumoral samples were suspended in Hank's buffer containing 1% of human serum albumin (Hank's/HSA) and 0.5% human Ig at a concentration of 2 × 10 7 cells/ml and incubated for 30 min at 4°C. The MI15 mAb was then added (1 g/10 6 cells) for 30 min at 4°C under gentle agitation. Unbound antibodies were removed by washing (twice at 400 g for 10 min at 4°C) and cells were resuspended in Hank's/HSA at a concentration of 2 × 10 7 cells/ml. Magnetic beads coated with sheep anti-mouse IgG (Dynal M450; Dynal, Oslo, Norway) were added at a ratio of four beads to one target cell and incubated for 30 min at 4°C under gentle agitation. The beads and rosetted cells were then captured with a magnet (MPC1; Dynal) and washed three times with the initial volume of Hank's/HSA in order to remove nonrosetted cells. Rosetted cells were resuspended in Hank's/HSA at an expected concentration of 10 7 cells/ml. Cells were released from the beads using chymopapain (Boots Pharmaceuticals, Nottingham, UK) at 200 pkat/ml for 20 min at room temperature under gentle agitation. The beads were captured with an MPC1 magnet and the procedure was repeated twice to ensure maximal bead capture. As previously published, 29 this purification procedure yielded highly purified myeloma cells (Ͼ95%). Myeloma cells were then resuspended in RPMI 1640 medium and 10% FCS.
Proliferation and growth assay of primary myeloma cells
Mononuclear cells from tumoral samples were cultured at 10 6 cells/ml in RPMI 1640 supplemented with 2 mM of L-glutamine and 10% of FCS. In some culture groups, an anti-IL-6 mAb (B-E8 mAb, 10 g/ml) or the agonist anti-gp130 mAb (B-S12 and B-P8, 0.5 g/ml each) and the anti-IL-6 mAb (B-E8 mAb, 10 g/ml) were added at the beginning of the culture. Control cultures were made with 10 g/ml of a mouse purified IgGl mAb recognizing no human antigens. After 5 days of culturing, cells were harvested and counted. The percentage of myeloma cells in the S-phase (LI) was evaluated using an antibromodeoxyuridine monoclonal antibody and a goat antikappa or anti-lambda Ig light chain antibody in a double immunofluorescence procedure described elsewhere. 9 The effect of the agonist anti-gp130 antibodies on the longterm growth of primary myeloma cells was evaluated with purified myeloma cells from 11 patients: three patients with medullary MM, five patients with primary PCL, two patients with secondary PCL and one patient with ascitis. Thirty million purified myeloma cells (10 6 cells/ml) were cultured with RMPI 1640 culture medium, 10% FCS and 1 g/ml control murine IgGl or with 1 g/ml of B-S12 and B-P8 anti-gp130 mAb (0.5 g/ml each). Every week, the cell number and the labeling index were determined as well as the membrane expression of IL-6R and gp130 by flow cytometry (see below). Every 3-4 days, half of the culture medium was replaced with fresh culture medium containing the initial antibody concentration.
Determination of cytokine receptors by FACS analysis
The expression of IL-6R and gp130 on the XG cell lines or primary myeloma cells was evaluated with FITC-conjugated mAb to IL-6R (M91) or to gp130 IL-6 transducer (B-T2) or with a FITC-conjugated murine IgGl mAb recognizing no human antigens as a control.
Western blotting
In order to assay for gp130-mediated induction of signal transduction in myeloma cells, XG cells were washed twice, cultured at 2 × 10 6 cells/ml without IL-6 for 12 h in RPMI 1640 and 1% of FCS at 37°C before B-S12 and B-P8 anti-gp130 mAb (50 g/ml each) were added for 1, 5, 10, 30 and 60 min. Cells were rapidly washed and immediately lysated at 4°C in 10 mM Tris-HCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate (NaPPi), 1% Triton X-100, 5 M ZnCl 2 , 100 M Na 3 VO 4 , 1 mM DTT, 20 mM ␤-glycerophosphate, 20 mM p-nitrophenolphosphate (PNPP), 2.5 g/ml aprotinin, 2.5 g/ml leupeptin, 0.5 mM PMSF, 0.5 mM benzamidin, 5 g/ml pepstatin and 50 nM okadaik acid. After preclearing at 14 000 g, soluble supernatant was resolved in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). Membranes were blocked for 1 h at room temperature in 140 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH 7.4), 0.1% Tween 20 (TBS-T), 6% bovine serum albumin (BSA), then incubated for 1 h at room temperature with primary antibody (phospho-specific STAT1, STAT3 or MAPK at 1:1000 dilution and anti-STAT1, STAT3 or ERK2 at 1:2000 dilution in 1% BSA TBS-T). The primary antibodies were visualized with goat anti-rabbit (Sigma) or goat anti-mouse (Biorad) peroxidase-conjugated antibodies (at 1:15 000 dilution in TBS-T, 5% skimmed milk) and by an enhanced chemiluminescence detection system. The membranes were stripped twice with 100 mM Glycin, pH 2.2, 0.1% NP 40 and 1% SDS for 30 min at room temperature.
Statistical analysis
For the cell lines, the mean values of tritiated thymidine incorporation or of cell numbers were compared using a t-test for small samples. The percentages of myeloma cells in the S phase (LI) were determined by examining at least 5000 cells. This ensures that these percentages were determined with a precision of ±2(LI(1 − LI)/5000) 1/2 and a risk of P Ͻ 0.05 as, for each LI considered (LI Ͼ 0.01), 5000 × LI was always greater than five. For primary myeloma cells, the mean values of the LI and of the myeloma cell numbers determined in the different culture groups were compared by using a t-test for pairs.
Results
Agonist anti-gp130 antibodies induce gp130-mediated signaling and support the long-term growth of IL-6-dependent myeloma cell lines
The growth of XG myeloma cell lines is dependent on an IL-6-mediated proliferation and survival signal: in the absence of IL-6, XG cells cease to proliferate and progressively die through apoptosis. 11, 30 The IL-6-mediated gp130 activation leads to two signaling pathways, one a Janus kinase signal transducer and activator of transcription (JAK/STAT) pathway, the other a mitogen-activated protein kinase (MAPK) pathway. 31 In order to evaluate to what extent the pair of agonist anti-gp130 mAb B-S12 + B-P8 can indeed activate a gp130-mediated signaling in MM cells, we analyzed by Western blot the phosphorylation status of main gp130 downstream proteins in the XG-2 cell line: STAT1 and STAT3 along the JAK/STAT pathway, ERK1 and ERK2 along the MAPK pathway. Results are shown in Figure 1 . Phosphorylation of STAT1 on tyrosine was observed within 5 min after addition of the pair of mAb to the cytokine deprived XG-2 cell line and it disappeared after 10 min. In order to control protein loading, the blot was re-probed with an antibody that recognizes STAT1 whatever its phosphorylation status. Phosphorylation of STAT3 was more sustained, readily detected after 1 min, maximum reached at 10 min before slowly declining. The anti-phospho-MAPK antibody recognized ERK1 (the upper 44 KDa band) and ERK2 (the lower 42 KDa band) phosphorylated on tyrosine after stimulation with the agonist antibodies. The kinetics paralleled that of STAT3 phosphorylation. These observations are similar to those obtained in XG-2 cells after stimulation with IL-6 (data not shown). Overall, these data strongly suggest that the pair of anti-gp130 mAb induces homodimerization of gp130, thus generating an identical signaling cascade to that of IL-6.
In agreement with the activation of a gp130-mediated signaling, Annexin-V staining experiments demonstrated that B-S12 + B-P8 blocked the apoptosis of myeloma cells induced upon removal of IL-6 (Figure 2a) . Furthermore, B-S12 + B-P8 induced proliferation of XG-1 and XG-2 cell lines to the same extent as IL-6 (Figures 2b and 3) . In fact the B-S12 mAb was weakly stimulatory but its effect was greatly enhanced by adding the B-P8 mAb at the same concentration as the B-S12 mAb (Figure 3a and b) . B-P8 mAb had no stimulatory activity alone. The effects of the anti-gp130 mAb on XG-1 and XG-2 proliferation were unaffected by neutralizing antibodies to IL-6 or IL-6R whereas IL-6 effects were completely blocked (Figure 3c and d) . As outlined in Figure 2b , an optimal proliferation was obtained for a concentration of antibody mixture (1:1) ranging from 1 g/ml to 100 g/ml. In the following experiments, the mixture of the agonist anti-gp130 mAb was used at a concentration of 1 g/ml (0.5 g/ml each). Finally, the pair of agonist anti-gp130 mAb B-S12 + B-P8 supported the long-term growth of most IL-6-dependent HMCL as strongly as IL-6 (Figure 4a-f) . However, the XG-6 HMCL was poorly stimulated, resulting in the accumulation of 1.5 log less cells when cultured for 3 weeks with the anti-gp130 mAb rather than with IL-6 (Figure 4c ). Nevertheless, a sensitive subclone, termed XG-6Ab could be obtained after 4 weeks of culture with the anti-gp130 mAb (Figure 4d ).
Figure 1
Tyrosine phosphorylation of STAT1, STAT3, ERK1 and ERK2 by agonist anti-gp130 transducer monoclonal antibodies. XG-2 cells were washed twice and starved of IL-6 for 12 h in RPMI 1640 and 1% of FCS at 37°C. They were stimulated with 100 g of B-S12 and B-P8 antibodies (50 g each) for 1-60 min. The lysate of the unstimulated or stimulated cells (1 × 10 6 cells per lane) was subjected to SDS-PAGE electrophoresis and immunoblotted with a phosphospecific antibody (P-STAT1, P-STAT3, P-MAPK). The blot was stripped and reprobed with an anti-STAT1, STAT3 or ERK2 antibody. Molecular weight markers on the right are in kilodaltons.
Agonist anti-gp130 antibodies induce the proliferation and the growth of primary myeloma cells
To determine proliferation of primary myeloma cells, unpurified tumoral samples were cultured for 5 days and then analyzed by flow cytometry using an anti-bromodeoxyuridine mAb. In agreement with our previous findings, 9 a spontaneous proliferation of myeloma cells was found in short-term cultures of primary tumor samples (Table 1) . This proliferation was inhibited by a monoclonal antibody to IL-6 (P = 0.0001). In the presence of this anti-IL-6 mAb, a mixture of B-S12 and B-P8 antibodies to gp130 (0.5 g each) restored the proliferation of primary myeloma cells (P = 0.0006). Similar results were obtained when cell growth was assessed by total cell count: the agonist anti-gp130 mAb prevented the decrease in
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Figure 2
Agonist anti-gp130 antibodies promote the survival and proliferation of IL-6 dependent myeloma cells. XG-2 myeloma cells were starved of IL-6 for 12 h and cultured for 3 days with graded concentrations of a mixture (1:1) of B-P8 and B-S12 anti-gp130 mAb or with 3 ng/ml of IL-6. 
Agonist anti-gp130 antibodies induce the growth of purified myeloma cells from patients with extramedullary proliferation and make it possible to obtain anti-gp130 mAb-dependent cell lines
To assay whether anti-gp130 mAb could support the longterm growth of primary myeloma cells, we purified tumoral cells from 11 patients in order to avoid the overcrowding of the cultures by bone marrow stromal cells. The purified cells, that contained more than 95% myeloma cells, were cultured for several weeks with 1 g/ml of the pair of anti-gp130 mAb (0.5 g each). We determined every week the myeloma cell number and the labeling index. For three patients with medullary involvement only, the anti-gp130 mAb induced a proliferation of myeloma cells lasting for 1-2 weeks. Representative results for one patient are shown in Figure 6b . After 1 week of culture, the proliferation rapidly declined and cells progressively died despite addition every 3-4 days of fresh culture medium and anti-gp130 mAb (Figure 6a ). This progressive
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Figure 3
Stimulation of XG myeloma cells by agonist anti-gp130 antibodies. (a,b) 10 4 XG-1 and XG-2 cells were cultured in 200 l of culture medium with no cytokine, or 100 pg/ml of IL-6 (IL-6), or various concentrations of B-P8 and B-S12 anti-gp130 mAb used alone or in combination. (c,d) 10 4 XG-1 and XG-2 cells were cultured in 200 l of culture medium with no cytokine, or 100 pg/ml of IL-6 (IL-6) or B-S12 + B-P8 antigp130 mAb (0.5 g each, B-S12 + B-P8) with or without 10 g/ml of an anti-IL-6 (Anti-IL-6) or anti-IL-6R mAb (Anti-IL-6R). The proliferation was assayed on day 4 of culture by determining the mean values of tritiated thymidine incorporation on sextuplate culture wells.
decline was not related to a loss of membrane gp130 expression on myeloma cells as assessed by flow cytometry with an anti-gp130 mAb recognizing an epitope different from the B-S12 and B-P8 epitopes (results not shown). For five patients with newly diagnosed primary PCL, we observed a transient proliferation lasting for 1-2 weeks. Myeloma cells, after an initial decline in cell number, survived for several weeks or months in the presence of agonist anti-gp130 antibodies. Representative results from two patients are shown in Figure 6c -f. For one patient, a 4-month survival was observed before the cultures became infected. For the other patients, myeloma cells died after 2. months of culturing. Without agonist anti-gp130 mAb, myeloma cells rapidly died. For two patients relapsing with extramedullary proliferation, one with plasma cell leukemia and one with ascitis, the anti-gp130 mAb induced a long-term growth of primary myeloma cells (Figure 6g-j) and two anti-gp130 mAb-dependent cell lines were obtained and termed XG-10 and XG-13. The growth of these cell lines was also supported by IL-6 (Figure 4e and f) . Without addition of anti-gp130 mAb, purified myeloma cells from these two patients failed to grow and progressively died within 4-5 weeks (Figure 6g and l) . Finally, for one patient with secondary PCL, purified myeloma cells survived and proliferated without addition of anti-gp130 mAb, and an autonomously growing cell line, termed XG-11, was obtained (results not shown).
Discussion
These experiments show that the pair of anti-gp130 mAb B-S12 + B-P8 is able to generate a gp130-mediated transduction signal in myeloma cells and to support the long-term growth of our various IL-6-dependent HMCL. The observation that these mAb induce an activation of the JAK/STAT and the MAPK pathways likely explains their potent survival and proliferation effect. STAT3 activation has been found to be critical for the anti-apoptosis signal mediated by gp130, 32 and this was recently confirmed. 33 It was shown that STAT3 is able to transactivate the Bcl-x L promoter and that a dominant negative Agonist anti-gp130 mAb support the long-term growth of IL-6-dependent myeloma cell lines. The XG-1, XG-2, XG-6, XG-6Ab, XG-10, XG-13 myeloma cells were starved of IL-6 for 5 h and then cultured at a concentration of 2 × 10 5 cells/ml with no cytokine (control) or 10 g/ml of a neutralizing anti-IL-6 mAb (Anti-IL-6), or 1 g/ml of the pair of agonist anti-gp130 mAb (0.5 g/ml each) without (Anti-gp130) or with 10 g/ml) of the neutralizing anti-IL-6 mAb (Anti-gp130 + Anti-IL-6) or with 3 ng/ml of IL-6 (IL-6). For each culture group, XG cells were diluted every 4 days at a cell concentration of 2 × 10 5 cells per ml in fresh culture medium containing the intial cytokine and/or antibody concentrations. The XG-6Ab HMCL was a subclone of the XG-6 HMCL cultured for 1 month with the agonist anti-gp130 antibodies. Results are means of the cumulative numbers of cells generated in triplicate culture wells.
STAT3␤ protein inhibits Bcl-x L expression and induces programmed cell death in the U266 HMCL. 33 The MAPK pathway is also involved in both IL-6-mediated cell survival and proliferation. 32, [34] [35] [36] Introduction of a mutated oncogenic ras gene in one IL-6-dependent myeloma cell line abrogates its cytokine dependence. 34 In addition, antisense oligonucleotides to ras mRNA block IL-6-induced proliferation. 36 The molecular and cellular data presented here strongly Leukemia suggest that the pair of agonist anti-gp130 mAb induces the homodimerization of the gp130 transducer chain. The B-S12 anti-gp130 mAb was slightly active alone but its activity was greatly enhanced by the B-P8 anti-gp130 mAb when added at the same concentration. The association of B-S12 and B-P8 appeared to be nearly as potent as IL-6 and IL-6R. By using these agonist antibodies, membrane gp130 is the only limiting event to trigger the gp130-mediated survival and pro- Table 1 The anti-gp130 antibodies (B-S12 and B-P8) stimulate the proliferation of primary myeloma cells ± 26.18 ± 1.62 ± 0.95 ± 2.15 P = 0.0001 P = 0.0006 10 6 mononuclear cells from tumoral samples from patients with MM were cultured for 5 days in culture medium alone (control) or with 10 g/ml of the neutralizing B-E8 mAb to IL-6 or with 10 g/ml of the neutralizing B-E8 mAb to IL-6 and 1 g/ml of a mixture (0.5 g/ml each) of the agonists B-S12 and B-P8 mAb to gp130. At the end of the culture, the percentages of myeloma cells in the S phase were determined by double immunofluorescence staining with an anti-bromodeoxyuridine mAb and an anti-immunoglobulin light chain antibodies. The means were compared with a t-test for pairs.
liferation signal to myeloma cells. In particular, one does not need to take into account the other components that are necessary to induce gp130 homo-or heterodimerization: IL-6, IL-6R or the other IL-6-related cytokines and their receptors such as IL-11 and IL-11R, LIF and LIFR, OSM and LIFR and OSMR, CNTF and CNTFR. This is especially relevant in the light of recent observations that soluble IL-6R may be a critical factor delivered by bone marrow stromal cells to primary myeloma cells. 21, 22 Moreover, other IL-6-related cytokines can substitute for IL-6 to sustain the growth of IL-6-dependent HMCL.
14 These cytokines may therefore play a role in the pathobiology of MM. Agonist anti-gp130 mAb circumvent all those potentially limiting factors in primary myeloma cell cultures and, since gp130 has an almost ubiquitous expression, they can deliver a gp130 signal whatever the membrane expression of the other IL-6-related cytokine receptors and whatever IL-6-related cytokines there are present in the culture medium.
To investigate the effect of the agonist anti-gp130 mAb on the long-term survival and growth of primary myeloma cells, we used highly purified myeloma cells. The purification procedure uses the anti-syndecan-1 mAb that recognizes all viable myeloma cells in tumoral samples. [27] [28] [29] Indeed, the cultures of non-purified myeloma cells are rapidly overcrowded by various stromal cells that hinder the follow-up of the longterm survival and growth of myeloma cells. Using such purified myeloma cells we observed, for all the patients, the death of about one half of the cells within the first days of culture which was likely due to the harvesting and purification procedure. Following this initial cell death, the growth pattern of myeloma cells makes it possible to distinguish three groups of patients. In the first group of patients, with medullary disease only, purified myeloma cells transiently proliferate for 1-2
Figure 5
Primary myeloma cell growth is stimulated by agonist anti-gp130 mAb. 10 6 Mononuclear cells per milliliter from tumoral samples of 10 patients with active MM were cultured for 5 days with no cytokine (control), or 10 g/ml of the B-E8 anti-IL-6 mAb (Anti-IL-6), or 1 g/ml of a mixture of B-S12 and B-P8 (0.5 g/ml each) antigp130 mAb and 10 g/ml of B-E8 anti-IL-6 mAb (Anti-gp130 + Anti-IL-6). Results are the mean myeloma cell counts on day 5 of culture expressed as the percentage of the mean myeloma cell count in the control group. Statistical analysis was carried out using the t-test for pairs.
weeks and survive for 2-4 weeks in the presence of agonist anti-gp130 mAb. Without mAb, they fail to proliferate and die within a few days. In a second group of patients, with newly diagnosed primary plasma cell leukemia, purified myeloma cells also proliferate for only 1-2 weeks, but survive for several months in vitro. Without mAb, tumoral cells fail to proliferate and to survive. Finally, in a third group of patients, presenting with fulminant relapse and extramedullary disease, myeloma cells survive and proliferate indefinitely with the anti-gp130 mAb and anti-gp130 mAb-dependent cell lines are obtained. Such various in vitro behaviors, precisely docu-
Figure 6
Long-term culture of purified myeloma cells with agonist anti-gp130 antibodies. Primary myeloma cells were purified from the bone marrow of one patient with medullary disease (a, b), peripheral blood from two newly diagnosed patients with primary plasma cell leukemia (c, d and e, f), from the peripheral blood of one patient with relapsing plasma cell leukemia (g, h) and from the ascitic fluid of one patient with myeloma ascitis (i, j) by using the anti-syndecan-1 MI15 mAb. Purified myeloma cells contained more than 95% myeloma cells. 30 × 10 6 Purified myeloma cells were cultured at a concentration of 10 6 cells/ml in culture medium alone and 1 g/ml of control murine IgGl (control) or with a mixture of 1 g/ml of B-S12 and B-P8 anti-gp130 mAb (0.5 g/ml each). Every week, the myeloma cell counts were determined (a, c, e, g, i) and half of the culture medium was replaced with fresh culture medium and 1 g/ml of control murine IgGl (control) or fresh culture medium containing 1 g/ml of the anti-gp130 mAb (anti-gp130). Every week, bromodeoxyuridine was added in one culture well for 1 h and the percentage of myeloma cells in the S phase was determined by using an anti-bromodeoxyuridine antibody (b, d, f, h, j) .
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Leukemia mented here with purified primary myeloma cells, fit with a generally accepted multi-step model of myeloma pathogenesis as reviewed by Hallek et al. 37 In intramedullary myeloma, the initial stage of the disease, the malignant cell needs the supportive environment provided by the bone marrow. Although gp130 activation is a survival signal, it is not sufficient to promote long-term survival. Other factors produced by stromal cells are likely to be important for triggering myeloma cell survival such as the insulin growth factor 1, interferon-alpha or TNF. [38] [39] [40] Fibroblast growth factor (FGF) might also be involved since translocations and activating mutations involving the FGF receptor 3 were recently reported in HMCL and primary myeloma cells from some patients, 41 and since the myeloma cell antigen syndecan-1 is an important FGF binding protein. 42 Survival co-signals might also be delivered by adhesion molecules that are largely present on myeloma cells, 43 and/or by the CD28 molecule that is a functional activation molecule on myeloma cells, 44 and/or by other activation molecules such as CD40 molecules that are expressed on primary myeloma cells. 45 The methodology presented in this paper should be very helpful in identifying such signals. Agonist anti-gp130 mAb directly activate the gp130 IL-6-transducer and thus allow focusing on factors acting in synergy with gp130 for medullary myeloma cell survival and proliferation. By contrast, in patients with plasma cell leukemia at diagnosis, myeloma cell survival in vivo no longer relies on a bone marrow stromal cell contact, which is likely due to additional mutations. In agreement, a gp130 signal is sufficient to deliver a strong survival signal for these cells in vitro, but it is not sufficient to trigger proliferation. In this setting we made the uncommon observation of tumoral cells that survive in vitro for months but do not grow. This phenotype is suggestive of replicative senescence. It has been proposed that replicative senescence could be a powerful tumor suppressive mechanism, blocking normal cell division beyond a given number -the Hayflick limit -or preventing neoplastic transformation when the MAPK signaling cascade is inappropriately active. 46, 47 Although this is an attractive hypothesis regarding the observed phenotype and the activation of ERK1 and 2 by the anti-gp130 mAb, this issue needs to be specifically addressed. In fulminant extra-medullary myeloma, usually affecting relapsing patients, a gp130-mediated signal is sufficient for both survival and proliferation, permitting unrestrained cell growth and thus establishment of HMCL. Genetic alterations such as ras and p53 mutations or loss of expression of p16 are more frequently found in this stage of the disease, which could account for the increased proliferation characteristics. [48] [49] [50] Finally, the properties of the agonist anti-gp130 mAb have permitted the generation of a murine model for human myeloma. 51, 52 Indeed, these murine antibodies have a 2-week half-life in vivo when injected in the mouse peritoneum and therefore appropriately replace the murine IL-6-type cytokines that do not activate human gp130. 53 Conversely, the agonist anti-gp130 mAb are not toxic for the mice because they do not recognize the mouse gp130. This generates a human gp130-mediated survival signal in the animal and makes it possible to obtain the growth of myeloma cells from HMCL and patients with active disease. Thus, this SCID model allows the preclinical study of various therapeutical agents in a system closest to the biology of MM.
